61/163US=85 / Biol/Mol
Park IJ, Lee YK, Hwang JT, Kwon DY, Ha J, Park OJ. Green tea catechin controls apoptosis in colon cancer cells by attenuation of H2O2-stimulated COX-2 expression via the AMPK signaling pathway at low-dose H2O2. In: Diederich M. Natural compounds and their role in apoptotic cell signaling pathways. Boston: Blackwell, 2009. p. 538-44. (Annals of the New York Academy of Sciences Vol 1171) ISBN 978-1-57331-737-5.

EGCG; COX-2; AMPK; HT-29 CANCER DE CELULAS DO COLON; BAIXAS DOSES DE H2O2; APOPTOSE; P53 TIPO SELVAGEM

62/163US=392 / Tese/FAP
Giesta RP. Estudo do valor preditivo e prognóstico de marcadores imunológicos no linfoma de Hodgkin clássico, no Ceará – Brasil. [Study of the predictive and prognostic value of immunological markers in the classic Hodgkin’s lymphoma, in Ceará - Brazil]. São Paulo, 2012. 143 p. Tese(Doutorado / Dinter)-Programa de Pós Graduação Interistitucional em Oncologia da Fundação Antônio Prudente/Escola Cearense de Oncologia.

Disponível em: http://accamargo.phlnet.com.br/Doutorado/2012/RogerioGiesta/RogerioGiesta.pdf

Curriculum Lattes

LINFOMA DE HODGKIN; PROGNOSTICO; MARCADORES IMUNOLOGICOS; CELULAS DE REED-STERNBERG; IMUNOHISTOQUIMICA; FORTALEZA

63/163US=23-D / Câncer
Zaika AI, Hong SM. Extrahepatic bile duct carcinoma: role of the p53 protein family. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: liver cancer. New York: Springer, 2009. p. 441-9. ISBN 978-1-4020-9803-1.

EXTRA-HEPATICO CARCINOMA DO DUCTO BILIAR; PROTEINA P53

64/163US=45-B / Cab/Pesc
Smith BD, Haffty BG. Prognostic factors in patients with head and neck cancer. In: Harrison LB, Sessions RB, Hong WK. Head and neck cancer: a multidisciplinary approach. 3rd ed. Philadelphia: J B Lippincott, 2009. p. 51-75. ISBN 978-0-7817-7136-8.

CANCER DE CABECA E PESCOCO; FATORES PROGNOSTICOS; NEOPLASIA PRIMARIA; LINFONODOS CERVICAIS; FATORES DEMOGRAFICOS; COMORBIDADE; ESTADO NUTRICIONAL; ANEMIA; FATORES PROGNOSTICOS MOLECULARES; P53; MARCADORES RELACIONADOS A ANGIOGENESE; CICLINA D1; RECEPTOR DO FACTOR DE CRESCIMENTO EPIDERMICO (EGFR)

65/163US=49-F / Câncer
Leeuwen IV,Lain S. Sirtuins and p53. In: Woude GFV, Klein G. Advances in cancer research. Amsterdam: Elsevier, 2009. p. 171-95. ISBN 978-0-12-3744371.

SIRTUINS E P53; SIRTUINS E DOENCA; SIRTUINAS NIVEIS E NA ATIVIDADE EM CELULAS CANCEROSAS; TERAPIAS

66/163US=29 / Biol/Mol
Watson JD, Myers RM, Caudy AM, Witkowski JA. Interpretando a base genética do câncer. In: DNA recombinante: genes e genomas. 3ª ed. Porto Alegre: Artmed, 2009. p. 396-429. ISBN 85-3631375-7.

GENOMICA HUMANA; DOENCAS; CANCER; FATORES AMBIENTAIS; DOENCA GENETICA; TRANSLOCACOES CROMOSSOMICAS; TECNICAS DE DNA RECOMBINANTE; PROTO-ONCOGENES CELULARES; CANCER DE MAMA; HERCEPTINA; GENES SUPRESSORES DE TUMOR; CANCER DO RETINOBLASTOMA FAMILIAR; PROTEINA P53; CANCER COLORRETAL; APOPTOSE; METASTASE; CANCER DE FIGADO; INIBIDORES DA TELOMERASE; POJETO GENOMA HUMANO

67/163US=19 / Cab/Pescoço
Smith IM, Califano JA, Ha PK. Molecular gene alterations as early-detection markers. In: Koch WM. Head and neck cancer. Philadelphia: Saunders Elsevier, 2010. p. 1-18. (Early diagnosis and treatment of cancer series) ISBN 978-1-4160-5202-9.

ALTERACOES GENETICAS MOLECULARES; MARCADORES DE DETECCAO PRECOCE; MARCADORES MOLECULARES; ANALISE DE LINFONODOS; MODELO DE PROGRESSAO DO CANCER; MECANISMOS DE DETECCAO DO CANCER; ALTERACOES CITOGENETICAS; DETECCAO DE PCR; P53; MITOCONDRIA; METILACAO; DETECCAO DE VIRUS; PAPILOMAVIRUS HUMANO; HPV; VIRUS EPSTEIN-BARR; CARCINOMA NASOFARINGEO; NIVEIS SERICOS DE MARCADORES DE PROTEINAS; CD44; RECEPTORES DOS FATORES DE CRESCIMENTO EPITELIAIS; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); TECNICAS PROTEOMICAS

68/163US=19 / Cab/Pescoço
Pattani KM. Chemoprevention of head and neck cancer. In: Koch WM. Head and neck cancer. Philadelphia: Saunders Elsevier, 2010. p. 81-93. (Early diagnosis and treatment of cancer series) ISBN 978-1-4160-5202-9.

CANCER DE CABECA E PESCOCO; QUIMIOPREVENCAO; RETINOIDES; BETA CAROTENO; VITAMINA E; ANTI-INFLAMATORIOS NAO-ESTEROIDES; SELENIO; INIBIDORES DE COX-2; ASPIRINA; RAS; RECEPTORES DE FATORES DE CRESCIMENTO EPIDERMICO; P53; CURCUMINA; INIBIDORES BOWMAN-BIRK; PAPILOMAVIRUS HUMANO; HPV; VACINA

69/163US=108 / Câncer
Fang B, Roth JA. Tumour-suppressor gene therapy. In: Harrington KJ, Vile RG, Pandha HS. Viral therapy of cancer. New Jersey: John Wiley & Sons, 2008. p. 229-39. ISBN 978-0-470-01922-1.

TERAPIA GENICA; GENE SUPRESSOR DE TUMOR; CANCER. TRATAMENTO; GENE P53

70/163US=13 / Biol/Mol
Pecorino L. Growth inhibition and tumor suppressor genes. In: ___. Molecular biology of cancer: mechanisms, targets, and therapeutics. 2nd ed. Oxford: Oxford University Press, 2008. p. 113-36. ISBN 978-0-19-921148-7.

CANCER; INIBICAO DO CRESCIMENTO DE TUMORES; GENES SUPRESSORES DE TUMORES; GENE DA RETINOBLASTOMA; MUTACAO DO RETINOBLASTOMA; GENE P53; MUTACAO NA VIA P53; SINDROME DE LI-FRAUMENI; INTERACAO DE PROTEINAS COM O DNA VIRAL; PAPILOMAVIRUS HUMANO (HPV); VIA P53

71/163US=13 / Biol/Mol
Pecorino L. Apoptosis. In: ___. Molecular biology of cancer: mechanisms, targets, and therapeutics. 2nd ed. Oxford: Oxford University Press, 2008. p. 137-59. ISBN 978-0-19-921148-7.

APOPTOSE; MECANISMOS MOLECULARES; VIA EXTRINSECA; VIA INTRISECA; RECEPTORES DE MORTE DA MEMBRANA; MITOCONDRIAS; GENE P53; CANCER; RECEPTORES TRAIL; QUIMIOTERAPIA; DROGAS ANTI-NEOPLASICAS APOPTOTICAS; BCL-2

72/163US=14 / Câncer
Bukhari MH, Niazi S, Anwar M, Chaudhry NA, Naeem S. Prognostic significance of new immunohistochemistry scoring of p53 protein expression in cutaneous squamous cell carcinoma of mice. In: Branicki FJ, Adem A, Ghazal-Aswad S, Torab FC. Recent advances in clinical oncology. Boston: Blackwell, 2008. p. 1-9. ISBN 978-1-57331-700-9.

IMUNOHISTOQUIMICA; P53; CARCINOMA DE CELULAS ESCAMOSAS

73/163Câncer
Costa H, Lima FO,Barrezueta LFM, Oshima CTF, Silva Júnior JA, Gomes TS, Artigiani Neto R, Franco M. Correlation between immunoexpression of BCL-2 protein family with apoptosis index, cellular proliferation and survival in colorectal carcinomas. Applied Cancer Research, São Paulo: Tecmedd, v.31, n.3, p. 74-80, 2011. ISSN 1980-5578.

Disponível em: http://accamargo.phlnet.com.br/applied/ACR2011;31p.74-80.pdf

APOPTOSE; PROLIFERACAO CELULAR; NEOPLASIAS COLORRETAIS; ANALISIS MICROARRAIS; PROTEINA BCL2

74/163US=28 / Biol/Mol
Dudley AC, Klagsbrun M. Tumor endothelial cell abnormalities. In: Teicher BA, Ellis LM. Antiangiogenic agents in cancer therapy. 2 ed. Houston: Humana Press, 2008. p. 73-84. ISBN 978-1-58829-870-6.

TUMORAIS ENDOTELIAIS ANORMALIDADES CELULARES; TUMOR; CELULAS ENDOTELIAIS; ANGIOGENESE; ANORMALIDADES CROMOSSOMICAS; RESISTENCIA A DROGAS; ESTROMA TUMORAL; P53

75/163US=23 / Câncer
Esposito NN, Dabbs DJ. Phyllodes tumours of the breast: prognostic assessment using immunohistochemistry. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: breast carcinoma. v.1. New York: Springer, 2008. p. 263-73. ISBN 978-1-4020-8368-6.

CANCER DE MAMA; TUMOR PHYLLODES; IMUNOHISTOQUIMICA; AVALIACAO PROGNOSTICA; MARCADORES DE PROLIFERACAO CELULAR; GENES SUPRESSORES DE TUMOR; P53; RECEPTORES DE ESTEROIDES; PROTEINAS; FATORES DE CRESCIMENTO EPIDERMICO; HER-2/NEU; ANALISE CROMOSSOMICA; ANALISE MOLECULAR; ANALISE HISTOPATOLOGICA

76/163US=35 / Biol/Mol
Levine AJ, Hu W, Feng Z. Tumor suppressor genes. In: Mendelsohn J, Howley PM, Israel MA,Gray JW, Thompson CB. The molecular basis of cancer. 3rd ed. Philadelphia: Saunders Elsevier, 2008. p. 31-8. ISBN 978-1-4160-3703-3.

GENES SUPRESSORES DE TUMOR; VIA P53-RB; IGF-1-MTOR

77/163US=35 / Biol/Mol
Dorsey FC, Steeves MA, Cleveland JL. Apoptosis, autophagy, and necrosis. In: Mendelsohn J, Howley PM, Israel MA,Gray JW, Thompson CB. The molecular basis of cancer. 3rd ed. Philadelphia: Saunders Elsevier, 2008. p. 205-20. ISBN 978-1-4160-3703-3.

APOPTOSE; AUTOFAGIA; NECROSE; CASPASES; FAMILIA BCL-2; MORTE CELULAR; NF-KEB; FATOR NUCLEAR KAPPA B; AKT/PTEN; ESTRESSE ONCOGENICO; P53

78/163US=23-A / Câncer
Toledo F. Role of TP53 mutations in cancer (an overview). In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods and overviews, lung carcinoma and prostate carcinoma. v.2. New York: Springer, 2008. p. 75-92. ISBN 978-1-4020-8441-62.

CANCER; MUTACAO; GENE TP53; CAPACIDADE DE TRANSATIVACAO P53

79/163US=39 / Câncer
Maina F, Dono R. p53 inhibitors as cancer sensitizing agents. In: Bonavida B. Sensitization of cancer cells for chemo/immuno/radio-therapy. Los Angeles: Humana Press, 2008. p. 189-202. ISBN 978-1-58829-989-5.

INIBIDORES P53; SENSIBILIZACAO DO CANCRO

80/163US=47 / Câncer
Klein C, Vassilev LT. Targeting the p53/MDM2 pathway for cancer therapy. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 19-56. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7.

SEGMENTACAO DA VIA P53/MDM2; TERAPIA DE CANCER; PROTEINA P53; MDM2; SUPRESSOR DE TUMOR; INTERACAO PROTEINA-PROTEINA; INTERACAO P53-MDM2

Primeira | Anterior | Próxima | Última